Enzychem Lifesciences Corporation (KOSDAQ:183490)

South Korea flag South Korea · Delayed Price · Currency is KRW
990.00
-27.00 (-2.65%)
Mar 25, 2026, 7:48 AM KST
Market Cap76.86B -29.6%
Revenue (ttm)67.75B -12.4%
Net Income-18.13B
EPS-234.00
Shares Out77.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume677,473
Average Volume797,042
Open1,003.00
Previous Close1,017.00
Day's Range986.00 - 1,012.00
52-Week Range937.00 - 1,766.00
Beta1.03
RSI37.55
Earnings DateApr 3, 2026

About Enzychem Lifesciences

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea. [Read more]

Sector Healthcare
Founded 1999
Employees 130
Stock Exchange KOSDAQ
Ticker Symbol 183490
Full Company Profile

Financial Performance

In 2025, Enzychem Lifesciences's revenue was 67.75 billion, a decrease of -12.44% compared to the previous year's 77.38 billion. Losses were -18.13 billion, -17.98% less than in 2024.

Financial Statements